DCF — ERLANGER MEDICAL CENTER
Enterprise Value: $-1.2B
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-1.2B
Enterprise Value
$-385.3M
PV of Cash Flows
$-791.6M
PV of Terminal Value
$-1.3B
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $1.1B | $-66.3M | -6.0% | $-113.7M | $-103.4M |
| Year 2 | $1.2B | $-56.7M | -5.0% | $-105.6M | $-87.3M |
| Year 3 | $1.2B | $-46.5M | -4.0% | $-96.9M | $-72.8M |
| Year 4 | $1.2B | $-41.8M | -3.0% | $-93.6M | $-64.0M |
| Year 5 | $1.3B | $-39.9M | -3.0% | $-93.3M | $-57.9M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-1.2B. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$1.1B
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.06411891932925126
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5